CORD-19:c654596857bce9cdd64ffc51842048643107348c / 129254-129498 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/c654596857bce9cdd64ffc51842048643107348c","sourcedb":"CORD-19","sourceid":"c654596857bce9cdd64ffc51842048643107348c","text":"The conclusion reached The ad interim findings show that LFX 500 mg od may guarantee per os an exposure similar to that achievable after iv administration, suggesting that sequential therapy may be considered effective in the treatment of LRTI.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T1076","span":{"begin":0,"end":244},"obj":"Sentence"},{"id":"T53908","span":{"begin":0,"end":244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T1076","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T53908","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"Epistemic_Statements","denotations":[{"id":"T190","span":{"begin":0,"end":244},"obj":"Epistemic_statement"}],"attributes":[{"subj":"T190","pred":"source","obj":"Epistemic_Statements"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T259","span":{"begin":0,"end":244},"obj":"Sentence"}],"attributes":[{"subj":"T259","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-HP","denotations":[{"id":"T169","span":{"begin":239,"end":243},"obj":"Phenotype"}],"attributes":[{"id":"A169","pred":"hp_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/HP_0002783"},{"subj":"T169","pred":"source","obj":"CORD-19-PD-HP"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ecd793","default":true},{"id":"Epistemic_Statements","color":"#bd93ec"},{"id":"CORD-19_Custom_license_subset","color":"#93eca3"},{"id":"CORD-19-PD-HP","color":"#ec939c"}]}]}}